UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Amendment No. 1)
|x||QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934|
|For the quarterly period ended July 31, 2012|
|o||TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934|
|For the transition period from to|
Commission File Number:001-34808
CHINA BOTANIC PHARMACEUTICAL INC.
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction of||(I.R.S. Employer|
|incorporation or organization)||Identification No.)|
Level 11, Changjiang International Building
No. 28, Changjiang Road, Nangang District, Harbin
Heilongjiang Province, China 150090
(Address of principal executive offices)
(Registrant’s Telephone Number, Including Area Code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
x Yes o No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
x Yes o No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
|Large accelerated filero||Accelerated filero|
|Non-accelerated filer o (Do not check if a smaller reporting company)||Smaller reporting companyx|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
o Yes x No
As of September 4, 2012, there were 37,239,536 shares of the registrant’s $0.001 par value common stock issued and outstanding.
China Botanic Pharmaceutical Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-Q/A (the “Amendment”) to the Company’s quarterly report on Form 10-Q for the period ended July 31, 2012 (the “Form 10-Q”), filed with the Securities and Exchange Commission on September 19, 2012 (the “Original Filing Date”), solely to furnish Exhibit 101 to the Form 10-Q in accordance with Rule 405(f)(3) of Regulation S-T. Exhibit 101 consists of the following materials from the Company’s Form 10-Q, formatted in XBRL (eXtensible Business Reporting Language):
|101.INS||XBRL Instance Document|
|101.SCH||XBRL Taxonomy Schema|
|101.CAL||XBRL Taxonomy Calculation Linkbase|
|101.DEF||XBRL Taxonomy Definition Linkbase|
|101.LAB||XBRL Taxonomy Label Linkbase|
|101.PRE||XBRL Taxonomy Presentation Linkbase|
No other changes have been made to the Form 10-Q. This Amendment speaks as of the Original Filing Date, does not reflect events that may have occurred subsequent to the Original Filing Date, and does not modify or update in any way disclosures made in the Form 10-Q.
Pursuant to Rule 406T of Regulation S-T, the interactive data files attached as Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.
Item 6. Exhibits
|31.1||Certification of Principal Executive Officer pursuant to Rules 13a-14 and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*|
|31.2||Certification of Principal Financial Officer pursuant to Rules 13a-14 and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*|
Certification of Principal Executive and Financial Officers pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
|101.INS||XBRL Instance Document (1)|
|101.SCH||XBRL Taxonomy Extension Schema (1)|
|101.CAL||XBRL Taxonomy Extension Calculation Linkbase (1)|
|101.DEF||XBRL Taxonomy Extension Definition Linkbase (1)|
|101.LAB||XBRL Taxonomy Extension Label Linkbase (1)|
|101.FRE||XBRL Taxonomy Extension Presentation Linkbase (1)|
*Previously filed with the Registrant’s Quarterly Report on Form 10-Q for the quarter ended July 31, 2012, as filed with the Securities and Exchange Commission on September 19, 2012.
(1) XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on our behalf by the undersigned, thereunto duly authorized.
|Date: September 20, 2012||CHINA BOTANIC PHARMACEUTICAL INC.|
|By:||/s/ Li Shaoming|
|Li Shaoming, Chief Executive Officer and President|
|(Principal Executive Officer)|
|Date: September 20, 2012||By:||/s/ Weiqiu Dong|
|Weiqiu Dong, Chief Financial Officer|
|(Principal Financial Officer)|